Tumor-targeted transferrin nanoassemblies delivering olaparib and curcumin for combating BCRP-mediated resistance in triple-negative breast cancer
TNBC tumor models, Olp-Cur@Trf NAs demonstrated extended blood circulation and active tumor accumulation, resulting in markedly superior tumor growth inhibition compared to the free drug combination. Importantly, these nanoassemblies were well-tolerated with minimal systemic toxicity, as evidenced by the absence of detectable damage to major organs. Collectively, our results validated the application of Olp-Cur@Trf NAs as a promising and practical therapeutic strategy to reverse BCRP-mediated chemoresistance in TNBC, with significant implications for clinical translation.
Authors
- Dengming Zhou
- Anam Razzaq
- Haroon Iqbal (ORCID: https://orcid.org/0000-0002-7908-8804)
- Asmat Ullah
- Naveed Ullah Khan
- Wang Yue
Institutions
- Guangdong Medical College (CN)
- Chinese Academy of Sciences (CN)
- Wenzhou Medical University (CN)
- Soochow University (CN)
- Affiliated Eye Hospital of Wenzhou Medical College (CN)
- Hangzhou Institute of Medicine, Chinese Academy of Sciences (CN)
- Zhejiang University of Technology (CN)
Publication Details
- Journal
- Biomaterials Science
- Published
- 2026-11-16
- DOI
- https://doi.org/10.1039/d6bm01277a
- Primary Topic
- Nanoparticle-Based Drug Delivery
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Chinese Academy of Sciences